World Health Organization’s Data (2024): Global Cancer Incidence and Mortality
Recently, the World Health Organization published its 2022 estimates regarding incidence and mortality worldwide, for 36 cancers, in 185 countries. According to this data, there were close to 20 million new cancer cases in 2022 and almost 10 million cancer patients died of the disease. The estimates suggest that approximately one in five men or […]
News Flash 6.2024
In the middle of June, the Food and Drug Administration approved Pembrolizumab (Keytruda) in combination with chemotherapy, followed by Keytruda alone, for the treatment of patients with advanced or recurrent endometrial cancer.The approval was supported by results from a clinical trial enrolling 810 patients with advanced or recurrent endometrial cancer. Patients were randomly assigned to […]
News Flash 1.2024
At the beginning of January, the Food and Drug Administration (FDA) approved the immunotherapy drug Pembrolizumab (Keytruda), in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer who had not previously received any treatment. The approval was based on results from a clinical trial in which 596 patients meeting the abovementioned […]
News Flash 12.2023
In the middle of December, the Food and Drug Administration (FDA) approved Enfortumab vedotin (Padcev) in combination with Keytruda (a type of immunotherapy) for the treatment of patients recently diagnosed with advanced or metastatic urothelial cancer. Padcev is an antibody-drug conjugate (an antibody attached to a chemotherapy agent). The antibody delivers the chemotherapy drug directly […]
News Flash 11.2023 (2)
In the middle of November, the Food and Drug Administration (FDA) approved Enzalutamide (Xtandi) for high risk prostate cancer patients with a rise in PSA levels following radical prostatectomy and/or radiotherapy. Xtandi (taken daily orally) works by preventing the connection of testosterone (a male sex hormone) to the cancer cells, thereby inhibiting their ability to […]
News Flash 11.2023 (1)
In the middle of November, the Food and Drug Administration (FDA) approved Pembrolizumab (Keytruda) in combination with chemotherapy, for the first-line treatment of patients with advanced unresectable or metastatic gastric or gastroesophageal junction cancer, not suitable for biological treatment. Keytruda, as mentioned previously, is an immunotherapeutic drug which helps the immune system to fight cancer cells. The […]
News Flash 10.2023
At the beginning of October, the Food and Drug Administration (FDA) approved Nivolumab (Opdivo) as an adjuvant treatment for patients (12 years and over) diagnosed with early stage melanoma (without lymph node involvement), following complete resection of the tumor with surgical safety margins. Opdivo – as well as Keytruda, which had been previously approved for […]
News Flash 5.2023
At the end of May, the Food and Drug Administration (FDA) approved Olaparib (Lynparza) with Abiraterone and Prednisone for the treatment of patients with advanced prostate cancer carring a BRCA mutation*, and for whom hormone therapy is no longer effective in arresting or slowing the disease. The approval is supported by the results of a […]
News Flash 3.2023
At the beginning of March, the Food and Drug Administration (FDA) approved treatment of Abemaciclib (Verzenio) for two years, combined with hormonal therapy, for early stage breast cancer patients with hormone receptor-positive HER2-negative tumors who underwent surgery and are at high risk of recurrence (i.e. either ≥4 axillary lymph node involvement, or 1-3 axillary lymph […]
News Flash 2.2023
At the beginning of February, the Food and Drug Administration (FDA) approved Sacituzumab govitecan (Trodelvy) for breast cancer patients with unresectable locally advanced or metastatic disease, whose tumors are hormone receptor-positive HER2-negative, and who have been treated with both endocrine therapy and chemotherapy*. Trodelvy is a targeted (biological) therapy called an anti-drug conjugate. It is […]